Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Ira M Jacobson

Showing results (31-40 of 186) with videos related to

Pageof 19
Sort By:
Cleveland Clinic Journal of Medicine|October 8, 2004
The role of hematopoietic growth factors in special populations with chronic hepatitis C: patients with HIV coinfection, end-stage renal disease, or liver transplantationStevan A Gonzalez, Ira M Jacobson
Liver International : Official Journal of the International Association for the Study of the Liver|January 5, 2013
Optimal treatment with telaprevir for chronic HCV infectionArun B Jesudian, Ira M Jacobson
Antiviral Therapy|November 29, 2012
The first wave: HCV NS3 protease inhibitors telaprevir and boceprevirKristen M Marks, Ira M Jacobson
Alimentary Pharmacology & Therapeutics|May 29, 2019
Editorial: bodybuilders bewareDavid M Feldman, Ira M Jacobson
Postgraduate Medicine|July 24, 2003
Slowing the progression of chronic hepatitis B. Early antiviral therapy can help minimize complicationsDavid B Purow, Ira M Jacobson
Clinics in Liver Disease|July 25, 2009
Telaprevir: hope on the horizon, getting closerIlan S Weisberg, Ira M Jacobson
Journal of Hepatology|May 24, 2011
Chronic hepatitis C genotype 2 and 3: are we ready for personalized medicine?Maya Gambarin-Gelwan, Ira M Jacobson
Current Gastroenterology Reports|December 14, 2011
Resistance-associated variants in chronic hepatitis C patients treated with protease inhibitorsMaya Gambarin-Gelwan, Ira M Jacobson
Journal of Viral Hepatitis|April 12, 2024
Monitoring for liver cancer post-gene therapy-How much and how often?Ype P de Jong, Ira M Jacobson
Journal of Hepatology|September 17, 2013
Antisense therapy for hepatitis C virus infectionYpe P de Jong, Ira M Jacobson
Pageof 19

Showing results (31-40 of 186) with videos related to

Sort By:
Pageof 19
Cleveland Clinic Journal of Medicine|October 8, 2004
The role of hematopoietic growth factors in special populations with chronic hepatitis C: patients with HIV coinfection, end-stage renal disease, or liver transplantationStevan A Gonzalez, Ira M Jacobson
Liver International : Official Journal of the International Association for the Study of the Liver|January 5, 2013
Optimal treatment with telaprevir for chronic HCV infectionArun B Jesudian, Ira M Jacobson
Antiviral Therapy|November 29, 2012
The first wave: HCV NS3 protease inhibitors telaprevir and boceprevirKristen M Marks, Ira M Jacobson
Alimentary Pharmacology & Therapeutics|May 29, 2019
Editorial: bodybuilders bewareDavid M Feldman, Ira M Jacobson
Postgraduate Medicine|July 24, 2003
Slowing the progression of chronic hepatitis B. Early antiviral therapy can help minimize complicationsDavid B Purow, Ira M Jacobson
Clinics in Liver Disease|July 25, 2009
Telaprevir: hope on the horizon, getting closerIlan S Weisberg, Ira M Jacobson
Journal of Hepatology|May 24, 2011
Chronic hepatitis C genotype 2 and 3: are we ready for personalized medicine?Maya Gambarin-Gelwan, Ira M Jacobson
Current Gastroenterology Reports|December 14, 2011
Resistance-associated variants in chronic hepatitis C patients treated with protease inhibitorsMaya Gambarin-Gelwan, Ira M Jacobson
Journal of Viral Hepatitis|April 12, 2024
Monitoring for liver cancer post-gene therapy-How much and how often?Ype P de Jong, Ira M Jacobson
Journal of Hepatology|September 17, 2013
Antisense therapy for hepatitis C virus infectionYpe P de Jong, Ira M Jacobson
Pageof 19